Skip to main content
    K

    Kazia Therapeutics Ltd ADR (KZIA)

    Official site

    HEALTHCARE ā€¢ BIOTECHNOLOGY ā€¢ NASDAQ

    $8.04
    -0.77 (-8.74%)

    Market Cap: $77.59M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    25%(1/4)
    Avg Surprise
    -18100.63%
    PeriodReportedEst.SurpriseB/MYoY
    Dec 25
    Reported Mar 16
    		$-0.58$-0.01-8205.17%Miss+98.1%
    Sep 25
    Reported Nov 7
    		$-7.64N/A+96.54%Beat+39.0%
    Jun 25
    Reported Jun 30
    		$-4.18$-0.01-64264.62%Miss+86.9%
    Mar 25
    Reported May 28
    		$-12.30$0.00N/AMiss+59.7%
    Sep 24
    Reported Nov 19
    		$-31.22$0.00N/AMiss+13.9%
    Dec 23
    Reported Mar 27
    		$-12.53$0.00N/ABeat-114.0%
    Dec 22
    Reported Mar 9
    		$-31.86$-24.65-29.27%Miss-530935.0%
    Jun 22
    Reported Oct 6
    		$-30.53N/AN/ABeat-500434.4%
    Dec 21
    Reported Jan 6
    		$-36.25N/AN/ABeat-158875.4%
    Jun 21
    Reported Sep 30
    		$-5.85N/AN/ABeat-27512.7%
    Mar 21
    Reported Jun 30
    		$-0.01$0.00N/AMiss+78.7%
    Dec 20
    Reported Mar 31
    		$-0.01$0.00N/AMiss+75.7%
    Sep 20
    Reported Dec 31
    		$-0.02$0.00N/AMiss+27.6%
    Jun 20
    Reported Sep 30
    		$-0.02$0.00N/AMiss+30.0%
    Mar 20
    Reported Jun 29
    		$-0.03$0.00N/AMiss-17.5%
    Dec 19
    Reported Mar 31
    		$-0.03$0.00N/AMiss-3.3%
    Sep 19
    Reported Dec 31
    		$-0.03$0.00N/AMiss+21.4%
    Jun 19
    Reported Sep 30
    		$-0.03$0.00N/AMiss+26.5%
    Mar 19
    Reported Jun 29
    		$-0.02$0.00N/AMiss+51.4%
    Dec 18
    Reported Mar 31
    		$-0.02$0.00N/AMiss-343.0%
    Sep 18
    Reported Dec 31
    		$-0.04$0.00N/AMiss-1279.4%
    Jun 18
    Reported Sep 30
    		$-0.04$0.00N/AMiss+68.3%
    Mar 18
    Reported Jun 29
    		$-0.05$0.00N/AMiss+4.3%
    Dec 17
    Reported Feb 21
    		$0.01$0.00N/ABeat+111.1%
    Sep 17
    Reported Dec 31
    		$0.00$0.00N/ABeat-
    Jun 17
    Reported Aug 30
    		$-0.13$0.00N/AMiss-
    Mar 17
    Reported Jun 30
    		$-0.05$0.00N/AMiss-
    Dec 16
    Reported Feb 22
    		$-0.09$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-14641.00%
    ROE-106.90%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio2.87xQuick Ratio2.87x
    Trading Statistics
    Beta2.27Avg Volume254.78K
    52-Week High$17.4052-Week Low$4.86

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$9.08
    SMA 20$9.61
    SMA 50$11.65
    SMA 200$10.45
    EMA 10$9.04
    EMA 20$9.68
    EMA 50$10.96
    EMA 200$10.76

    MACD

    Line: -0.86Signal: -0.83Hist: -0.02

    ADX

    ADX: 24.1+DI: 11.4-DI: 28.1

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down100.0
    PSAR$10.18

    Bollinger Bands

    Upper Band$11.06
    Lower Band$8.16
    %B Position3018%(Upper)
    Band Width-0.04

    RSI (14-Day)

    Oversold
    27.0

    Momentum Oscillators

    Stoch %K5.0
    Stoch %D6.4
    Williams %R-98.2
    ROC (10d)-17.5%
    Momentum-1.71
    CCI (20d)-175.5
    MFI (14d)23.1

    Volatility Measures

    ATR (14d)$0.73(9.0%)
    StdDev (20d)0.72
    Hist Vol65.2%(High)

    Volume Flow

    VWAP$8.33
    OBV79.2M
    AD Line-40.5M
    CMF (20d)-0.182

    Volume Metrics

    Avg Vol (20d)247.8K
    Vol Ratio1.1x
    VWMA (20d)$9.74

    Pivot Points

    R3$9.55
    R2$9.36
    R1$9.09
    Pivot Point$8.90
    S1$8.63
    S2$8.44
    S3$8.17

    Advanced Oscillators

    TSI-32.80
    Ultimate Osc27.8
    KST-241.83

    Financial Data

    QuarterDec 2025Sep 2025Jun 2025Dec 2024Sep 2024Jun 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022
    Total RevenueN/A$19,710$19,710$22,290$2.48M$2.48M$5$1,000N/A$278N/AN/A
    Cost of RevenueN/AN/A$0N/AN/A$0N/AN/AN/AN/AN/A$2.90M
    Gross ProfitN/A$19,710$19,710$22,290$2.48M$2.48M$5$1,000N/A$278$-626,204$-671,826
    Operating Expenses$13.30M$6.46M$6.46M$9.39M$22.06M$22.06M$8.88M$10.51MN/A$3.52M$13.64M$25.38M
    R&D$4.90M$2.96M$2.96M$4.28M$13.05M$13.05M$4.33M$6.20M$0$3.10M$9.36M$9.18M
    SG&A$0$0$3.51M$5.11M$9.01M$9.01M$4.56M$4.31M$0$2.15M$4.28M$2.63M
    Operating Income$-13,301,623$-4,848,616$-4,848,616$-9,368,384$-19,578,597$-19,578,597$-8,883,403$-10,509,514N/A$-5,255,021$-13,636,486$-25,382,135
    Interest Income$0$0$42,075$0$0$5,547$0$0$0$0$0$0
    Interest Expense$0$7.01M$0$1.22M$0$0$75,656$0$0$0$85,087$4.44M
    Income Before Tax$-12,322,167$-11,858,643$-11,858,643$-10,589,357$-18,089,941$-18,089,941$-8,959,059$-7,014,427$0$-3,507,349$-13,721,573$-11,864,313
    Income Tax Expense$0$-1,610,454$-1,610,454$-135,546$-135,454$-135,454$-135,546$-135,454$-67,773$67,773$-135,546$-52,106
    Net Income$-12,322,167$-9,951,035$-9,951,035$-10,453,811$-17,954,487$-17,954,487$-8,823,513$-6,878,973N/A$-3,439,576$-13,586,027$-11,812,207
    EBITDA$-13,301,623$-4,848,616$-4,848,616$-8,901,028$-18,644,302$-18,644,302$-7,948,698$-9,569,433N/A$-4,787,662$-12,701,745$-11,003,819
    EBITN/A$-4,848,616$-4,848,616$-9,368,384$-19,578,597$-19,578,597$-8,883,403$-10,509,514$-5,255,021$-5,255,021$-13,636,486$-11,938,528
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KZIA

    News

    Zero voting power is reported as a holder amends its Kazia Therapeutics (KZIA) passive stake report.

    Dauntless Investment Group, LLC has filed an amended passive investment disclosure (SCHEDULE 13G/A) for Kazia Therapeutics (KZIA), reporting beneficial ownership of 842,340 American Depository Shares...

    Stock Titanā€¢10/2/26ā€¢Neutral

    BTIG Maintains Kazia Therapeutics(KZIA.US) With Buy Rating, Maintains Target Price $40

    BTIG has reiterated its Buy rating on Kazia Therapeutics (KZIA.US) and maintained its price target of $40. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

    Moomooā€¢9/24/26ā€¢Bullish

    New rare-epilepsy trial unlocks milestone cash for Kazia (NASDAQ: KZIA)

    Kazia Therapeutics (NASDAQ: KZIA) has announced that its licensee, Sovargen Co., has dosed the first patient in a Phase 1b/2a clinical trial for paxalisib in patients with intractable epilepsy related to focal cortical...

    Stock Titanā€¢9/22/26ā€¢Bullish

    Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

    Kazia Therapeutics announced that its licensee, Sovargen Co., Ltd., has dosed the first patient in a Phase 1b/2a clinical trial of paxalisib for rare seizure disorders...

    PR Newswireā€¢9/22/26ā€¢Bullish

    Kazia Therapeutics (NASDAQ: KZIA) shifts ADSs to JPMorgan

    Kazia Therapeutics (KZIA) has appointed JPMorgan Chase Bank, N.A. as the sole depositary for its American Depositary Receipt (ADR) program, replacing The Bank of New York Mellon. This transition...

    Stock Titanā€¢9/19/26ā€¢Neutral

    KZIA Valuation and Fair Value

    Forward P/E
    12.8x
    PEG
    1.0x
    P/B
    0.8x
    See GNG's fair value

    KZIA Profitability: Margins, ROIC and FCF

    Operating margin
    -14641.0%
    Net margin
    0.0%
    ROE
    -106.9%

    KZIA Competitors

    CompanyTicker
    Lixte Biotechnology Holdings IncLIXT
    Pelthos Therapeutics Inc.PTHS
    Cardiff Oncology IncCRDF
    Telomir Pharmaceuticals, Inc. Common StockTELO
    Sera Prognostics IncSERA
    Nutriband IncNTRB
    Neuraxis, Inc.NRXS
    NeOnc Technologies Holdings, Inc. Common StockNTHI

    Sector: Healthcare

    KZIA Analyst Ratings

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    2
    Buy
    4
    Hold
    0
    Sell
    0
    Strong Sell
    0

    KZIA Bull Case vs Bear Case

    Bull case

    • KZIA grew quarterly revenue 312.4% year over year.
    • 100.0% of KZIA's analyst ratings are Buy or Strong Buy.

    Bear case

    • KZIA beat EPS estimates in 12.5% of its last 8 reported quarters.

    KZIA Earnings: Beat Rate and Next Report

    Beat rate
    1 of 8 quarters (12.5%)
    Average surprise
    -2712.6%

    Frequently Asked Questions About KZIA

    Does KZIA pay dividends?

    Kazia Therapeutics Ltd ADR (KZIA) does not currently pay a regular dividend.

    What is KZIA's market cap?

    Kazia Therapeutics Ltd ADR (KZIA) has a market capitalization of $77.59M with a current stock price of $8.04.

    Related stocks

    Sector: Healthcare

    All stocks starting with K

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In